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Abstract
Background: Intellectual disability (ID), autism, and epilepsy share frequent yet variable comorbidities with one another.
In order to better understand potential genetic divergence underlying this variable risk, we studied genes responsible for
monogenic IDs, grouped according to their autism and epilepsy comorbidities.
Methods: Utilizing 465 different forms of ID with known molecular origins, we accessed available genetic databases in
conjunction with gene ontology (GO) to determine whether the genetics underlying ID diverge according to its
comorbidities with autism and epilepsy and if genes highly penetrant for autism or epilepsy share distinctive
features that set them apart from genes that confer comparatively variable or no apparent risk.
Results: The genetics of ID with autism are relatively enriched in terms associated with nervous system-specific
processes and structural morphogenesis. In contrast, we find that ID with highly comorbid epilepsy (HCE) is modestly
associated with lipid metabolic processes while ID without autism or epilepsy comorbidity (ID only) is enriched at the
Golgi membrane. Highly comorbid autism (HCA) genes, on the other hand, are strongly enriched within the nucleus,
are typically involved in regulation of gene expression, and, along with IDs with more variable autism, share strong ties
with a core protein-protein interaction (PPI) network integral to basic patterning of the CNS.
Conclusions: According to GO terminology, autism-related gene products are integral to neural development. While it
is difficult to draw firm conclusions regarding IDs unassociated with autism, it is clear that the majority of HCA genes
are tightly linked with general dysregulation of gene expression, suggesting that disturbances to the chronology of
neural maturation and patterning may be key in conferring susceptibility to autism spectrum conditions.
Keywords: Mental retardation, Epilepsy, Epigenomics, Body patterning, Regulation of gene expression, Chromatin
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Background
Intellectual disability (ID), epilepsy, and autism are highly
comorbid with one another, suggesting shared etiologies
in at least some forms of these conditions. In both autism
and ID, epilepsy occurs in approximately one-third of
cases, respectively [1, 2]. In those individuals with epilepsy
eligible for surgery who have seizure onset prior to
24 months of age, approximately 46 % also have comorbid
ID [3]. Meanwhile, about 31 % of autistic children aged 8
have IQs within the ID range, and an additional 23 % fall
within the borderline region [4]. These high comorbidity
rates stress an etiological commonality among some
forms of the conditions, though it leaves unanswered
the question of which forms are more susceptible to
co-occurrence.
In recent years, there has been increased interest in
both the genetic and phenotypic overlap of ID, epilepsy,
and autism. Popular foci of study include monogenic
syndromes such as tuberous sclerosis (TSC), fragile X
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(FXS), and Angelman syndromes (AS), whose respective
gene mutations can to lead to disturbed neurogenesis
and various perturbations in neuroblast and neuronal
maturation. This can be inferred by the different yet
often overlapping malformations of cortical development
(MCD) found in these syndromes. TSC, for instance, is
defined in part by the characteristic tubers for which the
condition is so named, a form of multifocal cortical and
subcortical dysgenesis [5]. In FXS, features of macro-
cephaly and abnormalities of neuronal migration are also
sometimes noted [6, 7]. In addition, mouse models of
the syndrome have revealed alterations in neurogenesis
and early neuroblast differentiation, particularly affecting
the glutamatergic population [8]. Secondary microceph-
aly is likewise a feature in the majority of those with AS,
potentially resulting from disturbances in early neuro-
blast maturation and subsequent downstream effects on
neuronal differentiation and overall cortical structure
[9, 10]. In short, commonalities exist between these
conditions not necessarily in the precise malformations
encountered but in the general presence of MCD, though
they may sometimes require microscopic investigation in
order to identify. And in fact, numerous types of MCD are
commonly found across many forms of ID, epilepsy, and
autism, suggesting that these malformations may be indi-
cative of similar physiologies, e.g., excitatory-inhibitory
imbalance [11–14].
Because these three conditions overlap so frequently
and share phenotypic features such as MCD, we ques-
tioned whether the genetics of different forms of ID
might segregate according to their comorbidities with ei-
ther autism or epilepsy, indicating differences in their
etiological underpinnings. In particular, we find that ID
with high rates of autism comorbidity present with a




A comprehensive list of forms of ID were accessed from
the Mendelian Inheritance in Man (MIM) database [15].
Only conditions with known molecular basis were col-
lected. Keywords for initial search comprised “intellectual
disability”, “mental retardation”, “mentally retarded”, “glo-
bal developmental delay”, “severe developmental delay”,
and “profound developmental delay” (for a full listing of
OMIM numbers, gene/locus numbers, and associated
data, see Additional file 1). Conditions were then curated
and removed if: (1) the ID was not a primary feature but
was variably expressed; (2) the ID displayed onset later
than three years of age; (3) the condition tended to be le-
thal in infancy or early childhood; (4) the condition had a
known yet complex genetic etiology, e.g., large recombin-
ation events that include two or more genes (with the
exception of chromosome 2p16.3 deletion syndrome
which has been directly linked to NRXN1 mutations); (5)
autism was a defining symptom for diagnosis, as in the
cases of certain “susceptibility” genes; (6) only one or two
cases were noted in the literature; (7) mutations occurred
in only a single family; (8) the condition was a chromo-
some instability syndrome, leading to variable features due
to the accumulation of different mutations; or (9) a condi-
tion contained an unconfirmed or potentially spurious
mapping as indicated by a “?” before the disease name.
This led to a final list of 465 different forms of ID and 434
unique genes (some genes whose functions are unknown
were also removed from analyses although are still in-
cluded in the main list. In addition, a small selection of
genes was not recognized by gene ontology and therefore
was not included within those analyses. Therefore, gene
lists sometimes varied minimally between analyses).
Associated genes were assigned to one of five categories
according to the information available regarding their co-
morbidities with autism and epilepsy. This information
was initially derived from the MIM database and was sub-
sequently confirmed through thorough literature review.
Genes were additionally cross-referenced with Pinto et al.
[16], whose supplemental material includes a large list of
conditions associated with autism and ID. The categories
ultimately were: (1) ID with highly comorbid autism
(HCA) (N = 72 conditions, 71 genes), (2) ID with variable
autism (VarAut) (N = 139 conditions, 124 genes), (3) ID
with highly comorbid epilepsy (HCE) (N = 88 conditions,
86 genes), (4) ID with variable epilepsy (VarEp) (N = 84
conditions, 78 genes), and (5) ID without autism or epi-
lepsy (ID only) (N = 82 conditions, 75 genes) (Fig. 1a).
If a gene was redundant across two or more IDs, those
with occurrences of autism were preferentially given pref-
erence and placed within HCA or VarAut, followed by
epilepsy (HCE, VarEp), and so forth. Conditions were
assigned the above comorbidity groups if: (1) there was
even minor evidence of overlapping comorbidity reported
on MIM or in the broader literature; (2) if, in the case of
autism, the associated gene was included under “syn-
dromic”, “high confidence”, “strong candidate”, or “sug-
gestive evidence” headings in the SFARI Gene database or
rated 9+ within the AutismKB database; (3) there were no
reported instances of epilepsy/seizures but abnormal epi-
leptiform activity had been noted; or (4) the gene was in-
cluded in the epilepsy gene database, CarpeDB [17–19]. In
instances in which a single MIM condition had multiple
associated genes, all genes were placed in the same cat-
egory provided any of those were not already in a super-
seding category.
For the purposes of dividing all autism-associated IDs
into either the HCA or VarAut groups, any condition that
had ≥20 % autism comorbidity rating according to inten-
sive literature review was placed within the HCA category;
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meanwhile, all other IDs with at least two unrelated case
studies involving autism or autistic symptomology were
placed within VarAut (see Additional file 1 and Additional
file 2 for comorbidity references). For the purposes of
studying genetic penetrance, HCA and HCE conditions
were annotated according to their inheritance patterns
(dominant, recessive) and broken into their respective pat-
tern groups for further analysis.
Epileptic comorbidity was rated upon whether epilepsy
was reported in any cases within MIM or the larger lit-
erature and which were not apparently due to trauma or
another identifiable illness; in conditions in which the
reported N was low for the entire ID (≤3) and only one
or a few instances of epilepsy/seizure were noted, these
disorders were removed from the analysis entirely. Simi-
lar to autism, if epilepsy occurred only within a single
family, this condition was not included. For assessing
frequency of epilepsy, conditions were included in the
HCE group if seizures were listed as a common neuro-
logical feature for a given condition within the clinical
synopses portion of the MIM database, and this was
subsequently corroborated via literature search. The
same percentage cut-off for inclusion within HCE (20 %)
was used as in HCA.
Gene ontology
In order to assess associated gene product functions, we
analyzed differences in sample frequency for gene ontol-
ogy (GO) terms according to group across categories of
biological process, cellular component, and molecular
function [20]. A listing of significantly enriched terms
were initially accessed for each gene group, followed by
the removal of redundant parent terms and those un-
usable for direct annotation. Absolute frequencies were
then compared for each of these significant terms across
all groups. The prop.test() function in the statistical com-
puting software, R, was used for most statistical analyses.
All pairs of proportions were compared using a Chi-
square test of two proportions with one degree of free-
dom. A false discovery rate adjustment was applied to
account for multiple comparisons.
The same approach was used to study GO term en-
richment across HCA dominant x HCA recessive and
HCE dominant x HCE recessive conditions. Meanwhile,
Fig. 1 Gene ontology (GO) term enrichments across groups. a Proportional breakdown of the different comorbidity groups. b Morphogenesis and
nervous system-related GO term enrichments according to group. c GO term enrichments in processes related to gene expression regulation by group
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ratios of dominant:recessive in HCA vs. HCE were
assessed using a two-tailed heteroscedastic t test.
For more intensive examination, UniProt/Swiss-Prot
and Entrez Gene summaries of gene products’ molecular
functions were used as the basis to determine whether a
given gene was considered a nuclear epigenetic regulator
(transcription factor/repressor, methylator, ubiquitinase,
chromatin remodeler, etc.) [21, 22]. The same statistical
analyses as used in the main GO experiment were also
used here. For the purposes of studying rates of nuclear
epigenetic regulators across dominant x recessive sub-
groups, a proportions comparison was used, without need
for correction for multiple comparisons.
In addition, because a large minority of the HCA genes
are not currently included or rated within the SFARI Gene
Database, we compared the SFARI-only HCA group to
the HCA non-SFARI group in terms of number of nuclear
epigenetic regulators to ensure that no significant differ-
ences existed. This was performed using a two-tailed pro-
portions comparison.
Finally, a thorough literature search was performed to
determine which conditions within HCE and VarEp were
considered neurodegenerative. HCE and VarEp rates of
neurodegeneration were compared using a two-tailed
proportions comparison.
Protein-protein interaction networks
For the protein-protein interaction experiment, each gene
group was loaded individually into String 10 alongside a se-
lection of proteins representative of the core PPI network
(WNT=CTNNB1, SHH= PTCHD1, NCOR=NCOR1,
SWI/SNF = SMARCA1, NOTCH=NOTCH1, ERK1/2 =
FGF8, TGF-β/BMP = SMAD4), and confidence data were
analyzed [23]. Both the percentage of experimental genes
connected with the core PPI and the number of intermedi-
ary nodes that lay between the genes of interest and their
nearest core PPI neighbors were assessed according to
group. For the former analysis, a proportions test with cor-
rection for multiple comparisons was used; meanwhile, for
the latter, an ANOVA was utilized.
Results
Comorbidity data
We studied the comorbidities of a substantial list of IDs
with known molecular origins derived from the MIM
database. Of the 465 forms of IDs collected, we found that
45 % (N = 211) were comorbid with autism in at least a
minority of cases. Meanwhile, 15 % (N = 72) were highly
comorbid with autism, co-occurring in ≥20 % of reported
cases. Some of these include conditions well known for
autism association, such as FXS and TSC, however, also
included conditions less well known, such as non-
photosensitive trichothiodystrophy and Mowat-Wilson
Syndrome. Meanwhile, 44 % (N = 204) of IDs were highly
comorbid with epilepsy, while an additional 32 % (N =
151) exhibited variable rates of epilepsy. In fact, 55 %
(N = 116) of autism-related conditions listed epilepsy as
a common feature, which was consistent across both
HCA and VarAut groups, reinforcing ideas of their
shared etiologies (Table 1).
Trends in gene product function
We went on to study the genetic etiologies of our condi-
tions of interest, investigating GO term associations in the
areas of biological process, molecular function, and cellu-
lar component (see Table 2 for gene list by category). Both
autism groups, HCA and VarAut, exhibited enrichment in
nervous system development compared to HCE and ID
only (p = 0.0035–0.052, see Additional file 3 for full statis-
tical results). However, despite differences in this over-
arching parent term, our comorbidity groups did not
differ significantly in the child terms neurogenesis (p =
0.1218–0.8594), neuron differentiation (p = 0.3118–1.00),
neuron projection development (p = 0.2608–1.00), and syn-
aptic transmission (p = 0.5075–0.7988). HCA was mildly
enriched in the regulation of synaptic structure or activity
compared to HCE (p = 0.0477) and ID only (p = 0.0453),
but not compared to the variable groups. In summary,
both autism groups exhibit stronger nervous system en-
richment than either HCE or ID only, suggesting that
gene product involvement in nervous system develop-
ment may characterize a significant subset of autism
risk genes (Fig. 1b).
HCA was also particularly enriched in anatomical struc-
ture development compared to all groups (p = 0.0021–
0.0419) except VarAut (p = 0.2084), indicating the genes’
probable roles in structural morphogenesis (Fig. 1b). How-
ever, above all else, HCA was typified by regulation of gene
expression (p = 0.000–0.0404) and was involved in regula-
tion of DNA-templated transcription (p = 0.000–0.0406)
and chromatin binding (p = 0.0018–0.0326). Matching its
functional enrichment, HCA was strongly enriched
within the nucleus (p = 0.0002–0.0009) in contrast to all
other groups and was also modestly enriched at the
chromosome compared to HCE (p = 0.0392) and ID only
(p = 0.0416) (Fig. 1c).
UniProt/Swiss-Prot and Entrez Gene analysis further re-
vealed that HCA gene expression regulation was largely
carried out through nuclear epigenetic means, such as
transcription factors and repressors, methylation regula-
tors, ubiquitin ligases, and other chromatin remodelers,
which comprised over half of that gene group, a substantial
increase compared to all other comorbidity groups (p =
0.000–0.0004) (Fig. 2a). In addition, 45 % of the genes in
HCA are not currently included or rated within the SFARI
database, yet even with their removal, the SFARI-only
HCA group did not differ from those not included within
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Table 1 List of intellectual disabilities highly comorbid with autism, including gene symbols, SFARI ratings, estimates of autism
comorbidity, and indications of epilepsy comorbidity




Autism comorbidity References Epilepsy
frequency
Adenylosuccinase Deficiency (#103050) ADSL S 38 % (N = 8) Jaeken et al. 1988 [36] Common
Alpha-thalassemia/Mental Retardation Syndrome
(#301040)
ATRX 6 27 %, males (N = 73) Wada and Gibbons 2003 [37] Common
Angelman Syndrome (#105830) UBE3A S 79 % (N = 39) Bonati et al. 2007 [38] Common
Trillingsgaard and
Østergaard 2004 [39]
Autosomal Dominant Mental Retardation 1 (#156200) MBD5 3S 100 % (N = 14) Talkowski et al. 2011 [40] Common
Autosomal Dominant Mental Retardation 5 (#612621) SYNGAP1 1S 60 % (N = 10) Hamdan et al. 2011 [41] Common
Carvill et al. 2013 [42]
Berryer et al. 2013 [43]
Autosomal Dominant Mental Retardation 12 (#614562) ARID1B S 63 % (N = 8) Halgren et al. 2012 [44] Variable
Autosomal Dominant Mental Retardation 23 (#615761) SETD5 1S ≤71 % (N = 7) Grozeva et al. 2014 [45] No
evidence




Autosomal Dominant Mental Retardation 26 (#615834) AUTS2 3 41 % (N = 17) Beunders et al. 2013 [47] Variable
Autosomal Dominant Mental Retardation 30 (#616083) ZMYND11 3 29 % (N = 7) Coe et al. 2014 [48] Variable
Autosomal Recessive Mental Retardation 3 (#608443) CC2D1A 3 31 % (N = 16) Manzini et al. 2014 [49] Variable
Autosomal Recessive Mental Retardation 38 (#615516) HERC2 NS 86 % (N = 7) Puffenberger et al. 2012 [50] Common
Athabaskan Brainstem Dysgenesis Syndrome (#601536) HOXA1 S 22 % (N = 9) Tischfield et al. 2005 [51] Variable
Branched-chain Ketoacid Dehydrogenase Kinase
Deficiency (#614923)
BCKDK 3 100 % (N = 6) Novarino et al. 2012 [52] Variable
Brunner Syndrome (#300615) MAOA 4 71 %, males (N = 7) Piton et al. 2014 [53] Uncommon
Palmer et al. 2016 [54]
Cardiofaciocutaneous Syndrome 1 (#115150) BRAF NS 20 % (N = 15) Nava et al. 2007 [55] Common
Cardiofaciocutaneous Syndrome 3 (#615279) MAP2K1 NI 63 % (N = 8) Nava et al. 2007 [55] Common
Cerebral Creatine Deficiency Syndrome 1 (#300352) SLC6A8 4 68 % (N = 28) Dunbar et al. 2014 [56] Common
Cerebral Creatine Deficiency Syndrome 2 (#612736) GAMT NI 43 % (N = 7) Cheillan et al. 2012 [57] Common
Cerebral Creatine Deficiency Syndrome 3 (#612718) GATM NS 35 % (N = 20) Mercimek-Mahmutoglu et al.
2014 [58]
Variable
CHARGE Syndrome (#214800) CHD7 S 60 % (N = 10) Smith et al. 2005 [59] Variable
Childhood-onset Epileptic Encephalopathy (#615369) CHD2 2S 50 % (N = 6) Chénier et al. 2014 [60] Common
Christian-type of X-linked Syndromic Mental Retardation
(#300243)
SLC9A6 S 89 %, males (N = 9) Pescosolido et al. 2014 [61] Common
Chromosome 2p16.3 Deletion Syndrome (#614332) NRXN1 2 50 % (N = 40) Dabell et al. 2013 [62] Variable
Schaaf et al. 2012 [63]
Cohen Syndrome (#216550) VPS13B S 49 % (N = 45) Howlin et al. 2005 [64] Common
Congenital Rett Syndrome (#613454) FOXG1 5 100 % (N = 26) Kortüm et al. 2011 [65] Common
Cornelia de Lange Syndrome 1-5 (#122470, 300590,
610759, 614701, 300882)





Early Infantile Epileptic Encephalopathy 4 (#612164) STXBP1 NS 29 % (N = 7) Barcia et al. 2014 [67] Common
Early Infantile Epileptic Encephalopathy 6 (#607208) SCN1A S 24 % (N = 37) Li et al. 2011 [68] Common
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Table 1 List of intellectual disabilities highly comorbid with autism, including gene symbols, SFARI ratings, estimates of autism
comorbidity, and indications of epilepsy comorbidity (Continued)
Early Infantile Epileptic Encephalopathy 9
(#300088)
PCDH19 S 22 %, females (N = 27) Scheffer et al. 2008 [69] Common
Early Infantile Epileptic Encephalopathy 24
(#615871)
HCN1 NS 66 % (N = 6) Nava et al. 2014 [70] Common
Fragile X Mental Retardation Syndrome
(#300624)
FMR1 S 45 % (N = 64) Clifford et al. 2007 [71] Common
Glass Syndrome (#612313) SATB2 4 29 % (N = 7) Balasubramanian et al. 2011 [72] Common
Helsmoortel-Van der AA Syndrome (#615873) ADNP 1 100 % (N = 11) Helsmoortel et al. 2014 [73] Common
Pescosolido et al. 2014 [61]
KBG Syndrome (#148050) ANKRD11 33 % (N = 9) Ockeloen et al. 2014 [74] Uncommon
Kleefstra Syndrome (#610253) EHMT1 3S most, % unknown (N= 20) Willemsen et al. 2012 [75] Common
Lowe Oculocerebrorenal Syndrome (#309000) OCRL NS 71 %, males (N = 52) Oliver et al. 2011 [76] Common
Lubs X-linked Mental Retardation Syndrome
(#300260)
MECP2 S 100 %, males (N = 18) Ramocki et al. 2009 [77] Common
Lujan-Fryns Syndrome (#309520) MED12 6 ≤62 %, males (N = 32) Williams 2006 [78] Common
Marshall-Smith Syndrome (#602535) NFIX NI 83 % (N = 6) van Balkom et al. 2011 [79] Variable
Mental Retardation with Language Impairment
and Autistic Features (#613670)
FOXP1 3 75 % (N = 4) Le Fevre et al. 2013 [80] Variable
Mowat-Wilson Syndrome (#235730) ZEB2 NI 40 % (N = 6) Evans et al. 2012 [81] Common
Mucopolysaccharidosis, Type IIIA (#252900) SGSH NI 29 % (N = 73) Héron et al. 2011 [82] Common
Muscular Dystrophy-dystroglycanopathy (Congenital
with Mental Retardation), Type B3 (#613151)
POMGNT1 NS 22 % (N = 9) Hehr et al. 2007 [83] Variable
Myhre Syndrome (#139210) SMAD4 NS 25 % (N = 8) Caputo et al. 2012 [84] Variable
Myotonic Dystrophy 1 (#160900) DMPK S 49 % (N = 57) Ekström et al. 2008 [85] Variable
Neurodegeneration due to Cerebral Folate
Transport Deficiency (#613068)
FOLR1 NI 35 % (N = 20) Ramaekers and Blau 2004 [86] Common
Steinfeld et al. 2009 [87]
Nicolaides-Baraitser Syndrome (#601358) SMARCA2 NI 28 % (N = 18) Sousa et al. 2009 [88] Common
Noonan Syndrome 3 (#609942) KRAS NI 33 % (N = 6) Nava et al. 2007 [55] Uncommon
Nonphotosensitive Trichothiodystrophy 1
(#234050)
MPLKIP NI 60 % (N = 5) Heller et al. 2015 [89] Variable
Noonan Syndrome 3 (#609942) KRAS NI 33 % (N = 6) Nava et al. 2007 [55] Variable
Norrie Disease (#310600) NDP NI 27 %, males (N = 56) Smith et al. 2012 [90] Uncommon
Phelan-McDermid Syndrome (#606232) SHANK3 1S 52 % (N = 130) Phelan et al. 2001 [91] Common
Cusmano-Ozog et al. 2007 [92]
Dhar et al. 2010 [93]
Pitt-Hopkins Syndrome (#610954) TCF4 NS 75 % (N = 8) van Balkom et al. 2011 [79] Vommon
Renpenning Syndrome 1 (#309500) PQBP1 NI 38 %, males (N = 13) Germanaud et al. 2011 [94] Variable
Rett Syndrome (#312750) MECP2 S 100 %, females (N = 35) Hagberg et al. 1983 [95] Common
Schaaf-Yang Syndrome (#615547) MAGEL2 NS 100 % (N = 6) Schaaf et al. 2013 [96] Common
Soden et al. 2014 [97]
Smith-Lemli-Opitz Syndrome (#270400) DHCR7 S 75 % (N = 14) Sikora et al. 2006 [98] Common
Smith-Magenis Syndrome (#182290) RAI1 S 90 % (N = 26) Laje et al. 2010 [99] Common
Temtamy Syndrome (#218340) C12orf57 NS 100 % (N = 10) Akizu et al. 2013 [100] Common
Tuberous Sclerosis 2 (#613254) TSC2 S 40 % (N = 103) Numis et al. 2011 [101] Common
Warburg Micro Syndrome 4 (#615663) TBC1D20 NI 100 % (N = 7) Liegel et al. 2013 [102] Common
Wiedemann-Steiner Syndrome (#605130) KMT2A 2S 33 % (N = 6) Jones et al. 2012 [103] Variable
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the database in terms of their functional enrichment (p =
0.4501, Z = 0.8, Diff = −0.1436, 0.3236).
VarAut exhibited similar though more modest trends
in functional enrichment as seen within HCA, such as
regulation of gene expression (p = 0.0101) and regulation
of DNA-templated transcription (p = 0.0034), although
this was only apparent compared to HCE, the latter
which tended to house particularly low enrichment in all
of these terms.
HCE, VarEp, and ID Only did not show consistent dif-
ferences in enrichments in biological processes, with the
exception of HCE functional enrichment in lipid meta-
bolic processes compared to all groups (p = 0.0092–0.0486)
except VarEp (p = 0.1135). Compartmental enrichments
for the non-autism groups were also minimal, with the
exception of ID only enrichment within the Golgi mem-
brane compared to all groups (p = 0.0298) except VarEp
(p = 0.3132).
For more in-depth analysis, the HCA and HCE comor-
bidity groups were each divided in two according to
their patterns of inheritance (dominant vs. recessive)
and were compared against one another for significant
GO term enrichments. Significant functional enrich-
ments differentiated both sets of dominant and recessive
groups. HCA dominant genes, for instance, were com-
paratively more enriched than HCA recessive genes in
anatomical structure development (p = 0.0340), nervous
system development (p = 0.0126), cell differentiation (p =
0.0395), regulation of gene expression (p = 0.0033), regu-
lation of DNA-templated transcription (p = 0.0048), and
chromosome organization (p = 0.0232) (Fig. 2b). This
suggests that many of the significant GO terms associ-
ated with the larger HCA group are primarily driven by
this dominantly inherited subgroup.
Meanwhile, the HCE recessive gene group neared sig-
nificant enrichment in the term lipid metabolic process
compared to HCE recessive (p = 0.0561). In addition,
though they likewise did not reach significance, the reces-
sive group was also comparatively enriched in the endo-
plasmic reticulum as well as the endoplasmic reticulum
membrane (p = 0.0913). This suggests that disturbances to
protein trafficking through the cell, particularly the endo-
plasmic reticulum, may be a risk factor for recessive forms
of epilepsy.
Dominant HCE genes, in contrast, were enriched in
terms related to structural constituent of cytoskeleton (p =
0.0018), transmembrane transporter complex (p = 0.0003),
potassium ion transmembrane transporter (p = 0.0018),
protein complex (p < 0.0001), and myelin sheath (p =
0.007) (Fig. 2c). The functional significance of these asso-
ciations is not currently well understood.
These results together suggest that dominant and re-
cessive patterns of inheritance may diverge according to
gene function, though the reasons for this are currently
unknown. It is possible that haploinsufficiency may be
more or less detrimental according to broader groups of
protein function, leading to variations in penetrance. In
addition, we also found that the HCA group had a
higher ratio of dominant:recessive disorders than HCE,
though the relevance of this also cannot currently be de-
termined and may simply be a reflection of the divergent
classes of functional enrichment (p < 0.0001).
Protein-protein interaction network data
Upon further study of our gene groups, we find that nei-
ther of our autism groups differ significantly from one
another in their connectivity to the core PPI network, ei-
ther in the number of proteins that connect to the core
PPI (p = 0.1053) nor in the number of intermediary
nodes that lay between our proteins and their nearest
core PPI neighbor (network “tightness”) (p = 0.6098)
(Fig. 3c, d). In addition, HCA does not differ from HCE
in terms of the number of proteins that connect with
the network (p = 0.9151), but they do vary according to
Table 1 List of intellectual disabilities highly comorbid with autism, including gene symbols, SFARI ratings, estimates of autism
comorbidity, and indications of epilepsy comorbidity (Continued)
Wu Type of X-linked Syndromic Mental
Retardation (#300699)
GRIA3 NI 32 %, males (N = 6) Philips et al. 2014 [104] Common
X-linked Mental Retardation 1 (#309530) IQSEC2 NI 55 %, males (N = 9) Tran Mau-Them et al. 2013 [105] Uncommon
Shoubridge et al. 2010 [106]
X-linked Mental Retardation 72 (#300271) RAB39B 4 33 %, males (N = 9) Russo et al. 2000 [107] Common
Giannandrea et al. 2010 [108]
X-linked Mental Retardation 98 (#300912) KIAA2022 NS 43 %, males (N = 7) van Maldergem et al. 2013 [109] Common
X-linked Mental Retardation with or without
Seizures (#300419)
ARX S 50 %, males (N = 6) Turner et al. 2002 [110] Variable
X-linked Syndromic Mental Retardation 14
(#300676)
UPF3B S 50 %, males (N = 8) Tarpey et al. 2007 [111] Variable
Thirty-two of these genes are either not included in the SFARI Gene Database, are unscored, or are scored as a “6”. SFARI rating system: S = syndromic; 1 = high
confidence; 2 = strong evidence; 3 = suggestive evidence; 4 =minimal evidence; 5 = hypothesized; 6 = not supported; NI = not included, NS = included but not
scored (see Additional file 2 for references used to estimate comorbidities)
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Table 2 Full gene list by category
ID with highly comorbid
autism (HCA) N = 71
ID with variable autism
(VarAut) N = 124
ID with highly comorbid
epilepsy (HCE) N = 86
ID with variable epilepsy
(VarEp) N = 78
ID without autism or
epilepsy (ID only) N = 75
ADNP ACSL4 AASS ADAR AAAS
ADSL ACY1 ACTB ADCK3 ADAT3
ANKRD11 ADGRG1 ACTG1 ALDH3A2 AHDC1
ARID1B AFF2 ADK AP4B1 AIFM1
ARX AHI1 AGA AP4E1 ALX4
ATRX ALDH5A1 ALDH18A1 AP4S1 AP1S1
AUTS2 ALDH7A1 ALDH4A1 ARID1A AP4M1
BCKDK AP1S2 ALG13 ATIC ARSE
BRAF ARHGEF6 ALG6 BSCL2 B4GALT1
C12orf57 ASL ARG1 CACNG2 B4GALT7
CC2D1A BBS10 ARHGEF9 CDK5RAP2 BBS7
CHD2 BCKDHA ASPM CENPJ BRWD3
CHD7 BCKDHB ASXL1 CHMP1A C12orf65
DEAF1 BTD ATP1A2 COG8 C5orf42
DHCR7 CACNA1D ATP1A3 COL4A2 CA8
DMPK CAMTA1 ATP6V0A2 CSPP1 CASC5
EHMT1 CASK ATR CYP27A1 CDH15
FMR1 CBS CCDC88C DCAF17 CEP152
FOLR1 CC2D2A CLN5 DHTKD1 CLCNKB
FOXG1 CDKL5 CLN8 DIP2B COG1
FOXP1 CDON CLP1 DNMT3A COG6
GAMT CEP290 CTSA EIF2AK3 CRADD
GATM CEP41 CUL4B ESCO2 CRBN
GRIA3 CHKB D2HGDH FAT4 CTDP1
HCN1 CNTNAP2 DHCR24 FGF14 DDHD2
HDAC8 COG5 DHFR FGFR1 DDX59
HERC2 CREBBP DPM1 GALE DLAT
HOXA1 CTCF EFTUD2 GALT EMD
IQSEC2 CTNNB1 ELOVL4 GATAD2B ENTPD1
KIAA2022 DAG1 EPG5 GJC2 FGFR3
KRAS DBT ERLIN2 GRIN1 FTCD
MAGEL2 DCHS1 FAM126A HFE GIF
MAOA DCX FBXL4 IGF1 GMPPA
MAP2K1 DDC GABRA1 KAT6B GNPTAB
MBD5 DEPDC5 GMPPB KIAA1279 HPRT1
MECP2 DLG3 GRM1 KRAS IDUA
MED12 DMD KANSL1 LBR IGBP1
MLL DOCK8 KCNQ2 LINS1 INPP5E
MPLKIP DPYD KCNT1 MANBA IRX5
NDP DPYS KCTD7 MTRR KCNK9
NFIX DYM KIF5C MYCN KIF5A
NIPBL DYNC1H1 KPTN NIN LARGE
NRXN1 DYRK1A MGAT2 NTRK1 LARP7
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Table 2 Full gene list by category (Continued)
OCRL EP300 MLYCD OFD1 MAN2B1
PCDH19 FGFR2 MTR PEPD MED23
POMGNT1 FH NAGA PEX1 MIR17HG
PQBP1 FTSJ1 NDE1 PIGO NRAS
RAB39B GABRB3 NSDHL PORCN PACS1
RAD21 GDI1 OCLN PPOX PDE4D
RAI1 GLYCTK PAK3 PTCH1 PEX11B
SATB2 GNS PDHA1 PVRL1 PEX6
SCN1A GRIK2 PDX1 PYCR1 POLR3B
SETD5 GRIN2A PGAP2 RAB23 POMT2
SGSH GRIN2B PGAP3 RAB3GAP1 PRKAR1A
SHANK3 GSS PHGDH RAB3GAP2 PTDSS1
SLC6A8 HCFC1 PIGA RBBP8 RIT1
SLC9A6 HDAC4 PIGL SAMHD1 SKI
SMAD4 HEPACAM PIK3R2 SERAC1 SLC4A4
SMARCA2 HGSNAT PLP1 SIL1 SOS1
SMC1A HPD PNKP SIX3 SPTBN2
SMC3 HRAS PPT1 SLC12A6 TAF2
STXBP1 HUWE1 QARS SMARCA4 TBX1
SYNGAP1 IL1RAPL1 RAB18 SMARCB1 TECR
TBC1D20 KANK1 RANBP2 SOBP THOC6
TCF4 KCNH1 RNASET2 SOX3 TMCO1
TSC2 KCNJ10 RTTN SRD5A3 TMEM237
UBE3A KDM5C SEPSECS ST3GAL3 TMEM67
UPF3B KDM6A SLC19A3 STIL TTI2
VPS13B KIAA0196 SLC2A1 SYP UMPS
ZEB2 KIF7 SMS TAT UQCRQ
ZMYND11 KIRREL3 SNIP1 TBC1D7 WDR81
KMT2D SPTAN1 TMEM216 XYLT1
L1CAM ST3GAL5 TRAPPC9 YAP1
L2HGDH SZT2 UBE3B ZBTB16
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the tightness of the networks surrounding the core (p <
0.0001). Meanwhile, HCA and VarAut exhibit a larger
core network than both VarEp (p = 0.0001–0.0011) and
ID only (p = 0.0001–0.0003), but the level of network
tightness does not differ significantly. Overall, our aut-
ism groups exhibit a larger, tighter protein network sur-
rounding the core PPI compared to all other groups.
The core PPI network is a single extensive protein
network integral for patterning of the central nervous
system (e.g., dorsoventral patterning) as well as later
processes of neural maturation and ongoing plasticity.
This network includes morphogens such as Wingless
Integration Site (WNT), NOTCH, nuclear receptor co-
repressor (NCOR), SWItch/Sucrose Non-Fermentable
(SWI/SNF), Sonic Hedgehog (SHH), transforming
growth factor-β (TGF-β), bone morphogenetic proteins
(BMP), and extracellular signal-related kinase 1 and 2
(ERK1/2)—a functional module with considerable overlap
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with recent reports by Hormozdiari et al. [24] pinpoint-
ing a particularly enriched protein network in autism
that centers around WNT, NOTCH, SWI/SNF, and
NCOR [25].
Why the VarEp group diverged from HCE somewhat
in the String analysis, as well as various GO term enrich-
ments, is currently unknown. However, the HCE group
(N = 88) contained a significantly greater number of neu-
rodegenerative conditions compared to VarEp (N = 84)
(z = 2.5, p = 0.0119, Diff = 0.0375, 0.3025), suggesting that
the prevalence of neurodegeneration could underlie di-
vergence in their respective etiologies.
Discussion
Research implications
Despite that the rare conditions reported here within the
HCA group display very high rates of autism comorbidity,
genes associated with close to half of these conditions are
not currently included within the SFARI Gene Database,
are included but unscored, or are scored as “6” indicating
that the “evidence does not support a role in [autism
spectrum disorders]” (Table 1) [19]. In addition, 69 % of
HCA genes that are scored in SFARI but not considered
“syndromic” do in fact present with multiple physical dys-
morphia, such as complex craniofacial malformations,
Fig. 2 Additional functional and gene ontology (GO) enrichments. a Comparison across groups in number of nuclear epigenetic regulators.
b Comparison of GO terms across dominant vs. recessive HCA subgroups. c GO term enrichment across dominant vs. recessive HCE subgroups
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indicating that with further investigation, these genes
should and are likely to be subsumed under this umbrella
category.
Some of the non-SFARI conditions that are used in this
study are based on small numbers of patients and likely
require further in depth diagnostics to confirm the pres-
ence of autism symptoms in these conditions at a higher-
than-expected rate. In addition, a number of the studies is
also hampered by poor diagnostic methodology, an issue
that has plagued many of the earlier genetics studies,
whereas today’s gold standards include the use of the
ADOS and ADI-R as well as ID comparison groups for
the purposes of research. Most tellingly, however, the re-
moval of these conditions from the HCA group did not
change our results; genes with high penetrance for syn-
dromic and nonsyndromic autism are typically localized
to the nucleus and are involved in transcription regulation.
These results in particular stress the importance of group-
ing risk genes according to penetrance when possible, be-
cause this information was already present within the
SFARI database, though is currently lost amidst the other
genetic data.
Because genes associated with HCA are overrepresented
within the nucleus and tend to directly regulate transcrip-
tion, this suggests that mutation penetrance for autism
may be strongly linked with regulatory, as opposed to en-
zymatic, transduction, and structural, cellular networks
[26]. Transcription factors and regulators are the most
common examples within this group; however, other epi-
genetic regulators, such as heterochromatin remodelers,
ubiquitin ligases, and methylation regulators, were also
overrepresented. It may be for their phenotypic pene-
trance that dominantly inherited conditions were so com-
mon in the HCA comorbidity group.
In addition, the presence of gene subgroups within
HCA that share considerable overlap with a module for
autism risk reported by Hormozdiari et al. [24] suggests
that a significant portion of these cases, as well as those in
VarAut, are rooted in disturbances to patterning of the
CNS and ongoing deviations in neural maturation and
Fig. 3 Central nervous system patterning. a String 10 results for general interaction of the core PPI within itself. b General locations of the major
embryonic organizing centers of the central nervous system that underlie variations in its dorsoventral and rostrocaudal patterning. c Results
across groups for absolute connectivity of experimental proteins to the core PPI network. d Network tightness of proteins surrounding the core
PPI network, based upon the average number of intermediary nodes between a target protein and its nearest core PPI neighbor (Figure B adapted
from Wurst and Bally-Cuif. Nat Rev Neurosci 2001;2(2):99-108)
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plasticity. All of these morphogenetic pathways share con-
siderable crosstalk that is foundational to dorsoventral
and rostrocaudal patterning, planar cell polarity, locomo-
tion, neuritogenesis, and finally synaptogenesis and plasti-
city [25, 27–29]. If disturbed, they are likely to affect all
stages of neuronal development, spanning from the most
foundational to the most nuanced. Further work at the
cellular and tissue levels will be required to investigate
whether disturbances to patterning may play roles in these
conditions and how such patterning defects, alongside
later impairments to neuronal development and plasticity,
underlie the behavioral and neurological phenotypes.
In support of this, previous work investigating high-
risk autism-related genes has suggested that disturbances
to neural maturation may be a common theme to autism
[30]. Our present results indicate that epigenetic dys-
regulation could inappropriately suppress or prema-
turely promote the expression of gene products, leading
to chronological changes in the typical developmental
process and ultimately to gross structural, microstruc-
tural, and physiological perturbations.
For example, the fragile X mental retardation protein
(FMRP) associated with FXS normally aids in suppres-
sion of translation, thereby controlling timing of neural
differentiation. Instead, when the FMR1 gene is mutated
leading to decreased production of FMRP, neurogenesis
occurs prematurely [31]. These neurons also fail to ex-
press mature markers in a timely fashion (e.g., GAD67),
a disparity likely resulting in poor maturation and circuit
integration of adult neurons, and absolute or relative
macrocephaly, periventricular heterotopias, and volu-
metric increase in periventricular white matter, further
evidence of a pathological heterochrony and distur-
bances to patterning [6, 7, 32].
In contrast to our autism, variable epilepsy, and ID only
groups, ID with highly comorbid epilepsy exhibited par-
ticularly low enrichment in nervous system-specific pro-
cesses, was more often involved in lipid metabolism, and,
compared to conditions with variable epilepsy, had higher
rates of neurodegeneration. While this evidence is tantal-
izing, further work is needed to determine whether ID
and epilepsy related to neurodegenerative processes follow
a different etiological path than those related to general
nervous system development as may be seen in ID with
autism or variable epilepsies.
In contrast to the other groups, it was clear that the
HCA group is surprisingly homogeneous, suggesting that
risk for autism lies within a specific and very definable set
of molecular events that confer greater risk the further
downstream these elements are affected, i.e., at the level of
the gene and its product. This likewise suggests that the
further upstream a particular risk factor or environmental
effector, the more variable the penetrance for autism due
to the number of elements that may intercede and alter
events, e.g., feedback inhibition. This is strongly suggested
by the divergent compartmental enrichments seen in
HCA vs. VarAut, in which the former is highly enriched
for the nucleus while the latter is mildly enriched through-
out numerous cellular compartments and within cell pro-
jections in particular. Ultimately, risk is a threshold effect
and a risk factor must be closely upstream of its target
(e.g., in the case of epigenetic regulators) or, if further up-
stream, then it must be capable of avoiding feedback in-
hibition in order to reach threshold in a consistent highly
penetrant fashion (e.g., in the case of select sodium chan-
nel mutations).
On a similar note, factors that are comparatively less
penetrant yet still confer measurable risk suggest the
presence of additional variables, e.g., polygenic effects,
environmental agencies, etc., in the determination of
their etiologies. Given the nature of genetic selection,
common gene variants that provide variable autism risk
(i.e., common disease-common variant) are more likely
to explain a wider breadth of cases than the rare, often
de novo, mutations that confer higher penetrance for
the phenotype. Although interestingly, a recent study by
Alvarez-Mora et al. [33] reported that in a subset of
high-functioning cases they studied, over 50 % (6/11) of
the identified rare potentially deleterious single nucleo-
tide variants (SNV) occurred within the HCA genes re-
ported here, suggesting that these genes may be targets
with variable penetrance dependent upon the specific
type of mutation. Sanders et al. [34] have found that
highly penetrant deleterious SNVs tend to affect the
same genes that are also targets of small copy number
variants (CNV) in autism, such as occurs in the mono-
genic conditions studied here. Meanwhile, individual
genes that comprise larger CNVs each confer compara-
tively lesser risk. It is possible that if rare SNVs tend to
overlap HCA genes, less penetrant SNVs (e.g., common
variants) may overlap genes typically comprising larger
CNVs and reflect polygenic risk.
In the future, we may find that the genetics of autism
tends to diverge according to levels of severity, with rare
mutations (e.g., small and large CNVs, highly deleterious
rare SNVs) responsible for a significant portion of low-
functioning individuals with intellectual disability while
other rare SNVs and common variants, perhaps even
polygenic and/or environmentally driven, play important
roles in a larger portion of the moderate-to-high-func-
tioning ranges. This hypothesis is not entirely unlike that
proposed by Folstein [35] in which she suggests that aut-
istic individuals with profound ID, complex dysmorphic
features, or specific genetic conditions represent pheno-
types that are clinically unique compared to the idio-
pathic autism reported by Kanner. In this case, however,
we are suggesting that the genetics, though not necessar-
ily the overall biology, diverges between the two.
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Additional limitations
Aside from the limitations mentioned above concerning
questions of the diagnostic reliability of some of the HCA
conditions, additional shortcomings of this study involve
the availability of information regarding what are typically
rare conditions and potential underreporting regarding
comorbidities such as autism and epilepsy. There are, for
instance, a number of VarAut conditions in which case
studies or small group studies reporting autism incidence
are available but no larger studies have been performed in
order to provide better estimates of co-occurrence. Exam-
ples include conditions such as Succinic Semialdehyde
Dehydrogenase Deficiency (#271980), Autosomal Domin-
ant Mental Retardation 21 (#615502), and Dihydropyrimi-
dine Dehydrogenase Deficiency (#274270) to name just a
few that are likely worthy of more intensive study in rela-
tion to autism. Therefore, it is highly likely that some of
the conditions presented within this study have been mis-
categorized. In order to limit that occurrence to an abso-
lute minimum, various genetic databases were used in
conjunction with phenotypic data.
In addition, the fact that we limited our study of aut-
ism and epilepsy to forms of ID subsequently limits the
potential scope of applicability of our results, although
in doing so we were able to estimate comorbidity rates.
We therefore hope that future research may elucidate
which of the results presented here are applicable to the
broader autism spectrum or whether these data solely
define a subgroup of autism.
Because genetic mutations are infrequently identical
across different individuals with a single form of ID, it is
possible that some cases of autism or epilepsy within our
variable groups were not due to mutations involving the
primary gene associated with the monogenic condition
but were instead due to confounding effects of other
genes, such as may be seen in larger chromosomal rear-
rangements. However, most of the results presented here
exhibit strong functional patterns and therefore while in-
dividual IDs may ultimately be mis-categorized, we are
confident that the conclusions regarding the larger groups
are relatively sound.
Conclusions
While there were distinctive genetic differences between
groups, particularly between ID with autism vs. ID with-
out, the strongest findings within this study were over-
whelmingly those regarding the HCA group. In particular,
we find that the majority of genes that confer high risk for
autism are located within the nucleus and function as nu-
clear epigenetic regulators.
Our results also suggest that both autism groups rep-
resents a collection of disabilities that share not only
the autism and ID phenotypes, but also likely share de-
velopmental similarities in disruption to patterning of
the central nervous system. Further work by way of
molecular and animal studies is still needed to address
this hypothesis.
Aside from novel conclusions derived from the genetic
data presented here, we also hope that this curated list
may be useful for others and can be updated as new in-
formation becomes available. In addition, we hope that
this study can be used to inform further clinical research
in order to better update databases such as SFARI, af-
fecting research foci in future.
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